Dr. Griveas spoke on Saturday, May 6th ,at the Divani Caravel Hotel in Athens, at an event for “Hyperphosphatemia in Chronic Kidney Disease of End-Stage and treatment” demostrating "Real Life" data.
Data were presented regarding the fact that treatment of hyperphosphatemia with phosphorus binding agents in patients with Stage 5 CKD is associated with a high daily tablet load (αn average of 9), resulting in poor compliance with therapy and insufficient control of phosphorus levels. It has been shown that οnly 52% of patients receiving treatment achieve the desired phosphorus levels according to the KDOQI guidelines. The use of calcium-containing phosphorus-binding agents Is also associated with a risk of developing vascular calcifications. Nowdays, novel therapies give physicians more options for the treatment of hyperphosphatemia and CKD-MBD, according to each patient needs and requirements.